AIM ImmunoTech Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
AIM$0.14-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
December 31, 2024 and 2023
(in thousands, except for share and per share amounts)
| 2024 | 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,701 | $5,439 |
| Marketable securities | 2,276 | 7,631 |
| Funds receivable from New Jersey net operating loss | — | 1,184 |
| Prepaid expenses and other current assets | 199 | 302 |
| Total current assets | 4,176 | 14,556 |
| Property and equipment, net | 108 | 127 |
| Right of use asset, net | 618 | 697 |
| Patent and trademark rights, net | 2,594 | 2,313 |
| Other assets | 1,112 | 1,688 |
| Total assets | $8,608 | $19,381 |
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,383 | $6,443 |
| Accrued expenses | 606 | 1,986 |
| Current portion of operating lease liability | 239 | 223 |
| Current portion of note payable, net | 2,307 | — |
| Total current liabilities | 9,535 | 8,652 |
| Long-term liability: | ||
| Operating lease liability | 395 | 495 |
| Total liabilities | 9,930 | 9,147 |
| Commitments and contingencies (Notes 7, 8, 10, 16) | - | - |
| Stockholders’ (deficit) equity: | ||
| Series A Junior Participating Preferred Stock, $0.001 par value, 4,000,000 shares authorized as of December 31, 2024 and 2023; issued and outstanding – none | — | — |
| Series B Convertible Preferred Stock, stated value $1,000 per share, 10,000 shares authorized; no shares and 689 issued and outstanding as of December 31, 2024 and 2023, respectively | — | 689 |
| Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 65,526,320 and 49,102,484 as of December 31, 2024 and 2023, respectively | 66 | 49 |
| Additional paid-in capital | 425,440 | 419,004 |
| Accumulated deficit | (426,828) | (409,508) |
| Total stockholders’ (deficit) equity | (1,322) | 10,234 |
| Total liabilities and stockholders’ (deficit) equity | $8,608 | $19,381 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.